GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of “Reduce” from Analysts

GSK PLC Sponsored ADR (NYSE:GSK) has received an average recommendation of “Reduce” from the eleven research firms that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $44.1250.

Several analysts have recently issued reports on GSK shares. Jefferies Financial Group reissued a “buy” rating on shares of GSK in a research report on Monday, October 27th. HSBC reiterated a “reduce” rating on shares of GSK in a report on Wednesday, December 10th. Cfra set a $53.00 price target on shares of GSK in a research note on Thursday, October 30th. Citigroup reaffirmed a “neutral” rating on shares of GSK in a research report on Monday, February 9th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of GSK in a report on Friday, January 16th.

Insider Buying and Selling at GSK

In other news, major shareholder Plc Gsk purchased 1,470,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average price of $19.00 per share, for a total transaction of $27,930,000.00. Following the completion of the purchase, the insider directly owned 18,245,691 shares of the company’s stock, valued at $346,668,129. The trade was a 8.76% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 10.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of GSK during the 2nd quarter worth about $25,000. First Horizon Corp increased its stake in GSK by 78.7% in the fourth quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 236 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in GSK during the fourth quarter worth approximately $30,000. CNB Bank purchased a new stake in shares of GSK during the 3rd quarter worth approximately $31,000. Finally, CoreFirst Bank & Trust acquired a new position in shares of GSK in the 2nd quarter valued at $33,000. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Trading Up 0.7%

GSK opened at $58.93 on Wednesday. GSK has a 52 week low of $32.38 and a 52 week high of $60.37. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.92. The business has a fifty day simple moving average of $50.94 and a 200-day simple moving average of $45.73. The firm has a market cap of $120.13 billion, a P/E ratio of 15.93, a P/E/G ratio of 3.57 and a beta of 0.46.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 9th. Stockholders of record on Friday, February 20th will be given a dividend of $0.4856 per share. This is a boost from GSK’s previous quarterly dividend of $0.42. This represents a $1.94 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Friday, February 20th. GSK’s dividend payout ratio is presently 45.95%.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.